Anc80 encoding sphingolipid-metabolizing proteins for mitigating disease-induced tissue damage

Abstract

The present disclosure relates generally to the use of sphingolipid-metabolizing proteins to mitigate or minimize tissue damage resulting from injury or from disease, for example, pulmonary arterial hypertension (PAH) when the sphingolipid-metabolizing protein is delivered via expression from an Anc80 vector.

Dependencies are inferred from the claim text.